Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4527454 | 1.00 | TLR7 (0.39) | TLR7HDAC1HDAC8HDAC6HDAC11 | |
| SCHEMBL4537564 | 0.80 | TLR7 (0.39) | TLR7HDAC1HDAC8HDAC6HDAC11 | |
| SCHEMBL4539872 | 0.79 | TLR7 (0.42) | TLR7HDAC1HDAC8HDAC6HDAC11 | |
| SCHEMBL4539875 | 0.79 | TLR7 (0.42) | TLR7HDAC1HDAC8HDAC6HDAC11 | |
| SCHEMBL1895853 | 0.76 | TLR7 (0.53) | TLR7TLR8PIK3CANUDT1 | |
| SCHEMBL3862141 | 0.75 | TLR7 (0.45) | TLR7TLR8NUDT1 | |
| SCHEMBL4519462 | 0.69 | TLR7 (0.42) | TLR7HDAC1HDAC8HDAC6HDAC11 | |
| SCHEMBL1897263 | 0.68 | TLR7 (0.58) | TLR7TLR8NUDT1 | |
| SCHEMBL6719547 | 0.68 | TLR7 (0.51) | TLR7TLR8PIK3CANUDT1 | |
| SCHEMBL3863839 | 0.67 | TLR7 (0.46) | TLR7TLR8BRD4NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658666-B2 | Substituted imidazoquinolines and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-02-25 | — | — | US | disclosed |
| US-20090099161-A1 | Substituted Imidazoquinolines and Imidazonaphthyridines | COLEY PHARMACEUTIAL GROUP, INC. (NY) | 2009-04-16 | — | — | US | disclosed |
| EP-1845988-A2 | SUBSTITUTED IMIDAZOQUINOLINES AND IMIDAZONAPHTHYRIDINES | 3M Innovative Properties Company (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006091394-A2 | SUBSTITUTED IMIDAZOQUINOLINES AND IMIDAZONAPHTHYRIDINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099161-A1 | Substituted Imidazoquinolines and Imidazonaphthyridines | IL2, EIF2AK2, IFNG | TLR7 35/4885HDAC1 562/4885HDAC8 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.